The licensing agreement with a large US biotech is excellent news and illustrates the commercial potential of Abzena’s ThioBridgeTM platform for the design of better antibody-drug conjugate (ADC) drugs. Under the terms of the agreement, Abzena will receive an upfront payment, further milestones of up to $150m and a royalty on potential sales. We re-iterate our positive stance.
